Astra Zeneca has announced a 12% growth in their first half of 2019 product sales, and an acceleration in their second quarter product sales.
Astra Zeneca has seen a rise in revenue for the fourth successive quarter, Sales numbers were boosted by oncology drugs, Tagrisso, Imfinzi and Lynparza as well as a 27% increase in sales with China.
“Astra Zeneca announced strong product sales for the first half of 2019“
Commenting on the success, Pascal Soriot, chief executive officer said “the momentum generated last year continued into the first half of this year, and the strength of our new medicines cemented our return to growth. Five of our new medicines are anticipated to have a huge impact in supporting sales across the Oncology and BioPharmaceuticals markets, where we say a strong growth the UK and Japan.”